Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD

P. M. A. Calverley, Z. Cseke, S. Peterson (Liverpool, United Kingdom; Szombathely, Hungary; Lund, Sweden)

Source: Annual Congress 2003 - Pharmacological treatment strategies in COPD
Session: Pharmacological treatment strategies in COPD
Session type: Thematic Poster Session
Number: 436
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. M. A. Calverley, Z. Cseke, S. Peterson (Liverpool, United Kingdom; Szombathely, Hungary; Lund, Sweden). Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD. Eur Respir J 2003; 22: Suppl. 45, 436

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Budesonide/formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroids in patients with mild persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 387s
Year: 2002

Budesonide/formoterol single inhaler therapy is well tolerated and reduces systemic steroid use
Source: Eur Respir J 2004; 24: Suppl. 48, 310s
Year: 2004

Efficacy of inhaled ciclesonide compared with oral prednisolone in the treatment of asthma exacerbations
Source: Eur Respir J 2006; 28: Suppl. 50, 206s
Year: 2006

The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 290s
Year: 2004

Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Budesonide/formoterol for maintenance and relief vs. higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS)
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007


Switching asthma patients using high-dose inhaled steroids to budesonide/formoterol maintenance and reliever therapy
Source: Annual Congress 2010 - Management of airway disease
Year: 2010

Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Evening administration of tiotropium during combination therapy reduces night-symptoms in COPD patients
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases
Year: 2008


Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Year: 2020




Short-acting bronchodilator and oral steroid use in asthma patients prescribed either concurrent beclometasone and salmeterol or combined salmeterol/fluticasone
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

Comparison of oral prednisolone and nebulized budesonide in the treatment of acute exacerbations of COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 214s
Year: 2001

Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001

Concomitant use of low-dose inhaled corticosteroids and a long-acting bronchodilatator visavi doubling the dose of inhaled corticosterod in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 98s
Year: 2001

Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function
Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Year: 2020




Budesonide/formoterol maintenance and reliever therapy compared to conventional best practice in the treatment of persistent asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 616s
Year: 2007

Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 426s
Year: 2001

Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD)
Source: Eur Respir J 2004; 24: Suppl. 48, 252s
Year: 2004

Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011


Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 43s
Year: 2001